According to previous studies [38], patients on EGFR inhibitors, either cetuximab or panitumumab, are at higher risk of thromboembolism, especially with venous thromboembolism (VTE), than those not treated with EGFR inhibitors. Here, EGFR is linked to venous thromboembolism.